The DOI matches its Crossref record; 84 of the 84 references it cites were found in a registry or an index.
Gene therapy using genetically modified lymphocytes targeting VEGFR-2 inhibits the growth of vascularized syngenic tumors in mice
Open accessAbstract
Immunotherapies based on adoptive cell transfer are highly effective in the treatment of metastatic melanoma, but the use of this approach in other cancer histologies has been hampered by the identification of appropriate target molecules. Immunologic approaches targeting tumor vasculature provide a means for the therapy of multiple solid tumor types. We developed a method to target tumor vasculature, using genetically redirected syngeneic or autologous T cells. Mouse and human T cells were engineered to express a chimeric antigen receptor (CAR) targeted against VEGFR-2, which is overexpressed in tumor vasculature and is responsible for VEGF-mediated tumor progression and metastasis. Mouse and human T cells expressing the relevant VEGFR-2 CARs mediated specific immune responses against VEGFR-2 protein as well as VEGFR-2-expressing cells in vitro. A single dose of VEGFR-2 CAR-engineered mouse T cells plus exogenous IL-2 significantly inhibited the growth of 5 different types of established, vascularized syngeneic tumors in 2 different strains of mice and prolonged the survival of mice. T cells transduced with VEGFR-2 CAR showed durable and increased tumor infiltration, correlating with their antitumor effect. This approach provides a potential method for the gene therapy of a variety of human cancers.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The biology of VEGF and its receptors
Ferrara, N., Gerber, H.-P., & LeCouter, J. (2003) · Nature Medicine · doi:10.1038/nm0603-669 · Cited by 9,591
Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis
Hanahan, D., & Folkman, J. (1996) · Cell · doi:10.1016/s0092-8674(00)80108-7 · Cited by 6,885
Mechanisms of angiogenesis and arteriogenesis
Carmeliet, P. (2000) · Nature Medicine · doi:10.1038/74651 · Cited by 4,162
Modes of resistance to anti-angiogenic therapy
Bergers, G., & Hanahan, D. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2442 · Cited by 2,953
Cancer Regression and Autoimmunity in Patients After Clonal Repopulation with Antitumor Lymphocytes
Dudley, M. E., Wunderlich, J. R., Robbins, P. F., Yang, J. C., Hwu, P., Schwartzentruber, D. J., Topalian, S. L., Sherry, R., Restifo, N. P., Hubicki, A. M., et al. (2002) · Science · doi:10.1126/science.1076514 · Cited by 2,823
Self-citationCD28/B7 SYSTEM OF T CELL COSTIMULATION
Lenschow, D. J., Walunas, T. L., & Bluestone, J. A. (1996) · Annual Review of Immunology · doi:10.1146/annurev.immunol.14.1.233 · Cited by 2,717
Cancer regression in patients after transfer of genetically engineered lymphocytes
Morgan, R. A., Dudley, M. E., Wunderlich, J. R., Hughes, M. S., Yang, J. C., Sherry, R. M., Royal, R. E., Topalian, S. L., Kammula, U. S., Restifo, N. P., et al. (2006) · Science · doi:10.1126/science.1129003 · Cited by 2,603
Self-citationPàez-Ribes, M., Allen, E., Hudock, J., Takeda, T., Okuyama, H., Viñals, F., Inoue, M., Bergers, G., Hanahan, D., & Casanovas, O. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.01.027 · Cited by 2,339
Integrin αvβ3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels
Brooks, P. C., Montgomery, A. M. P., Rosenfeld, M., Reisfeld, R. A., Hu, T., Klier, G., & Cheresh, D. A. (1994) · Cell · doi:10.1016/0092-8674(94)90007-8 · Cited by 2,262
Angiogenesis: an organizing principle for drug discovery?
Folkman, J. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2115 · Cited by 2,246
Immunosuppressive networks in the tumour environment and their therapeutic relevance
Zou, W. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1586 · Cited by 2,057
Induction of angiogenesis during the transition from hyperplasia to neoplasia
Folkman, J., Watson, K., Ingber, D., & Hanahan, D. (1989) · Nature · doi:10.1038/339058a0 · Cited by 1,879
Accelerated Metastasis after Short-Term Treatment with a Potent Inhibitor of Tumor Angiogenesis
Ebos, J. M. L., Lee, C. R., Cruz-Munoz, W., Bjarnason, G. A., Christensen, J. G., & Kerbel, R. S. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.01.021 · Cited by 1,709
Dudley, M. E., Wunderlich, J. R., Yang, J. C., Sherry, R. M., Topalian, S. L., Restifo, N. P., Royal, R. E., Kammula, U., White, D. E., Mavroukakis, S. A., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.00.240 · Cited by 1,639
Self-citationHeinzel, F. P., Sadick, M. D., Holaday, B. J., Coffman, R. L., & Locksley, R. M. (1989) · The Journal of experimental medicine · doi:10.1084/jem.169.1.59 · Cited by 1,454
Johnson, L. A., Morgan, R. A., Dudley, M. E., Cassard, L., Yang, J. C., Hughes, M. S., Kammula, U. S., Royal, R. E., Sherry, R. M., Wunderlich, J. R., et al. (2009) · Blood · doi:10.1182/blood-2009-03-211714 · Cited by 1,418
Self-citationDudley, M. E., Yang, J. C., Sherry, R., Hughes, M. S., Royal, R., Kammula, U., Robbins, P. F., Huang, J., Citrin, D. E., Leitman, S. F., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.5449 · Cited by 1,332
Self-citationThe Regulation of Immunity to Leishmania major
Reiner, S. L. (1995) · Annual Review of Immunology · doi:10.1146/annurev.immunol.13.1.151 · Cited by 1,297
A Phase I Study on Adoptive Immunotherapy Using Gene-Modified T Cells for Ovarian Cancer
Kershaw, M. H., Westwood, J. A., Parker, L. L., Wang, G., Eshhar, Z., Mavroukakis, S. A., White, D. E., Wunderlich, J. R., Canevari, S., Rogers-Freezer, L., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1183 · Cited by 1,254
Self-citationMilone, M. C., Fish, J. D., Carpenito, C., Carroll, R. G., Binder, G. K., Teachey, D., Samanta, M., Lakhal, M., Gloss, B., Danet-Desnoyers, G., et al. (2009) · Molecular Therapy · doi:10.1038/mt.2009.83 · Cited by 1,197
Pule, M. A., Savoldo, B., Myers, G. D., Rossig, C., Russell, H. V., Dotti, G., Huls, M. H., Liu, E., Gee, A. P., Mei, Z., et al. (2008) · Nature Medicine · doi:10.1038/nm.1882 · Cited by 1,195
Marincola, F. M., Jaffee, E. M., Hicklin, D. J., & Ferrone, S. (1999) · Advances in Immunology · doi:10.1016/s0065-2776(08)60911-6 · Cited by 1,174
Yang, L., DeBusk, L. M., Fukuda, K., Fingleton, B., Green-Jarvis, B., Shyr, Y., Matrisian, L. M., Carbone, D. P., & Lin, P. C. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.08.031 · Cited by 1,140
Indoleamine 2,3-dioxygenase and tumor-induced tolerance
Munn, D. H., & Mellor, A. L. (2007) · Journal of Clinical Investigation · doi:10.1172/jci31178 · Cited by 1,078
Gattinoni, L., Finkelstein, S. E., Klebanoff, C. A., Antony, P. A., Palmer, D. C., Spiess, P. J., Hwang, L. N., Yu, Z., Wrzesinski, C., Heimann, D. M., et al. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20050732 · Cited by 1,061
Self-citationHuman T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRζ /CD28 receptor
Maher, J., Brentjens, R. J., Gunset, G., Rivière, I., & Sadelain, M. (2002) · Nature Biotechnology · doi:10.1038/nbt0102-70 · Cited by 1,034
Clinical applications of angiogenic growth factors and their inhibitors
Ferrara, N., & Alitalo, K. (1999) · Nature Medicine · doi:10.1038/70928 · Cited by 1,004
Overwijk, W. W., Theoret, M. R., Finkelstein, S. E., Surman, D. R., de Jong, L. A., Vyth-Dreese, F. A., Dellemijn, T. A., Antony, P. A., Spiess, P. J., Palmer, D. C., et al. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20030590 · Cited by 925
Self-citationLamers, C. H. J., Sleijfer, S., Vulto, A. G., Kruit, W. H. J., Kliffen, M., Debets, R., Gratama, J. W., Stoter, G., & Oosterwijk, E. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.05.9964 · Cited by 915
Carpenito, C., Milone, M. C., Hassan, R., Simonet, J. C., Lakhal, M., Suhoski, M. M., Varela-Rohena, A., Haines, K. M., Heitjan, D. F., Albelda, S. M., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0813101106 · Cited by 888
Adoptive immunotherapy for cancer: building on success
Gattinoni, L., Powell, D. J., Rosenberg, S. A., & Restifo, N. P. (2006) · Nature Reviews Immunology · doi:10.1038/nri1842 · Cited by 845
Self-citationTill, B. G., Jensen, M. C., Wang, J., Chen, E. Y., Wood, B. L., Greisman, H. A., Qian, X., James, S. E., Raubitschek, A., Forman, S. J., et al. (2008) · Blood · doi:10.1182/blood-2007-12-128843 · Cited by 722
Prewett, M. C., Huber, J., Li, Y., Santiago, A., O'Connor, W., King, K. D., Overholser, J. C., Hooper, A. T., Pytowski, B., Witte, L., et al. (1999) · PubMed · Cited by 713
North, R. J. (1982) · The Journal of experimental medicine · doi:10.1084/jem.155.4.1063 · Cited by 650
Park, J. R., DiGiusto, D. L., Slovak, M., Wright, C., Naranjo, A., Wagner, J., Meechoovet, H. B., Bautista, C., Chang, W.-C., Ostberg, J. R., et al. (2007) · Molecular Therapy · doi:10.1038/sj.mt.6300104 · Cited by 603
Spratlin, J. L., Cohen, R. B., Eadens, M., Gore, L., Camidge, D. R., Diab, S., Leong, S., O'Bryant, C., Chow, L. Q. M., Serkova, N. J., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.7537 · Cited by 549
Zhong, X.-S., Matsushita, M., Plotkin, J., Riviere, I., & Sadelain, M. (2010) · Molecular Therapy · doi:10.1038/mt.2009.210 · Cited by 543
Hanenberg, H., Xiao, X. L., Dilloo, D., Hashino, K., Kato, I., & Williams, D. A. (1996) · Nature Medicine · doi:10.1038/nm0896-876 · Cited by 542
Finney, H. M., Akbar, A. N., & Lawson, A. D. G. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.1.104 · Cited by 467
Robbins, P. F., Dudley, M. E., Wunderlich, J., El-Gamil, M., Li, Y. F., Zhou, J., Huang, J., Powell, D. J., & Rosenberg, S. A. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.173.12.7125 · Cited by 463
Self-citationMaus, M. V., Thomas, A. K., Leonard, D. G. B., Allman, D., Addya, K., Schlienger, K., Riley, J. L., & June, C. H. (2002) · Nature Biotechnology · doi:10.1038/nbt0202-143 · Cited by 454
Goldman, C. K., Kendall, R. L., Cabrera, G., Soroceanu, L., Heike, Y., Gillespie, G. Y., Siegal, G. P., Mao, X., Bett, A. J., Huckle, W. R., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.15.8795 · Cited by 443
Effect of p53 Status on Tumor Response to Antiangiogenic Therapy
Yu, J. L., Rak, J. W., Coomber, B. L., Hicklin, D. J., & Kerbel, R. S. (2002) · Science · doi:10.1126/science.1068327 · Cited by 426
Dominant-negative inhibition of Flk-1 suppresses the growth of many tumor types in vivo.
Millauer, B., Longhi, M. P., Plate, K. H., Shawver, L. K., Risau, W., Ullrich, A., & Strawn, L. M. (1996) · PubMed · Cited by 413
Construction and Preclinical Evaluation of an Anti-CD19 Chimeric Antigen Receptor
Kochenderfer, J. N., Feldman, S. A., Zhao, Y., Xu, H., Black, M. A., Morgan, R. A., Wilson, W. H., & Rosenberg, S. A. (2009) · Journal of Immunotherapy · doi:10.1097/cji.0b013e3181ac6138 · Cited by 408
Self-citationA DNA vaccine against VEGF receptor 2 prevents effective angiogenesis and inhibits tumor growth
Niethammer, A. G., Xiang, R., Becker, J. C., Wodrich, H., Pertl, U., Karsten, G., Eliceiri, B. P., & Reisfeld, R. A. (2002) · Nature Medicine · doi:10.1038/nm1202-794 · Cited by 400
Cutting Edge: 4-1BB Is a Bona Fide CD8 T Cell Survival Signal
Takahashi, C., Mittler, R. S., & Vella, A. T. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.162.9.5037 · Cited by 379
A cancer therapy resistant to resistance
Kerbel, R. S. (1997) · Nature · doi:10.1038/36978 · Cited by 369
Masood, R., Cai, J., Zheng, T., Smith, D. L., Hinton, D. R., & Gill, P. S. (2001) · Blood · doi:10.1182/blood.v98.6.1904 · Cited by 343
Witte, L., Hicklin, D. J., Zhu, Z., Pytowski, B., Kotanides, H., Rockwell, P., & Böhlen, P. (1998) · Cancer and Metastasis Reviews · doi:10.1023/a:1006094117427 · Cited by 307
Zhao, Y., Wang, Q. J., Yang, S., Kochenderfer, J. N., Zheng, Z., Zhong, X., Sadelain, M., Eshhar, Z., Rosenberg, S. A., & Morgan, R. A. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0900447 · Cited by 293
Self-citationSimon, M., Grone, H. J., Johren, O., Kullmer, J., Plate, K. H., Risau, W., & Fuchs, E. (1995) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.1995.268.2.f240 · Cited by 288
Kuo, C. J., Farnebo, F., Yu, E. Y., Christofferson, R., Swearingen, R. A., Carter, R., von Recum, H. A., Yuan, J., Kamihara, J., Flynn, E., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.081615298 · Cited by 271
Dirkx, A. E. M., Egbrink, M. G. A. O., Castermans, K., van der Schaft, D. W. J., Thijssen, V. L. J. L., Dings, R. P. M., Kwee, L., Mayo, K. H., Wagstaff, J., Steege, J. C. A. B., et al. (2006) · The FASEB Journal · doi:10.1096/fj.05-4493com · Cited by 270
Hurtado, J. C., Kim, Y. J., & Kwon, B. S. (1997) · The Journal of Immunology · doi:10.4049/jimmunol.158.6.2600 · Cited by 257
Immunotherapy of tumors with xenogeneic endothelial cells as a vaccine
Wei, Y.-Q., Wang, Q.-R., Zhao, X., Yang, L., Tian, L., Lu, Y., Kang, B., Lu, C.-J., Huang, M.-J., Lou, Y.-Y., et al. (2000) · Nature Medicine · doi:10.1038/80506 · Cited by 233
Hughes, M. S., Yu, Y. Y. L., Dudley, M. E., Zheng, Z., Robbins, P. F., Li, Y., Wunderlich, J., Hawley, R. G., Moayeri, M., Rosenberg, S. A., et al. (2005) · Human Gene Therapy · doi:10.1089/hum.2005.16.457 · Cited by 231
Self-citationWang, J., Jensen, M., Lin, Y., Sui, X., Chen, E., Lindgren, C. G., Till, B., Raubitschek, A., Forman, S. J., Qian, X., et al. (2007) · Human Gene Therapy · doi:10.1089/hum.2007.028 · Cited by 213
Manning, E. A., Ullman, J. G. M., Leatherman, J. M., Asquith, J. M., Hansen, T. R., Armstrong, T. D., Hicklin, D. J., Jaffee, E. M., & Emens, L. A. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0374 · Cited by 205
Christofori, G. (1995) · Molecular Endocrinology · doi:10.1210/me.9.12.1760 · Cited by 198
Padró, T., Bieker, R., Ruiz, S., Steins, M., Retzlaff, S., Bürger, H., Büchner, T., Kessler, T., Herrera, F., Kienast, J., et al. (2002) · Leukemia · doi:10.1038/sj.leu.2402534 · Cited by 197
Lu, D., Shen, J., Vil, M. D., Zhang, H., Jimenez, X., Bohlen, P., Witte, L., & Zhu, Z. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m307742200 · Cited by 183
IFN-γ– and TNF-dependent bystander eradication of antigen-loss variants in established mouse cancers
Zhang, B., Karrison, T., Rowley, D. A., & Schreiber, H. (2008) · Journal of Clinical Investigation · doi:10.1172/jci33522 · Cited by 167
Synergy between tumor immunotherapy and antiangiogenic therapy
Nair, S., Boczkowski, D., Moeller, B., Dewhirst, M., Vieweg, J., & Gilboa, E. (2003) · Blood · doi:10.1182/blood-2002-12-3738 · Cited by 163
Li, Y., Wang, M.-N., Li, H., King, K. D., Bassi, R., Sun, H., Santiago, A., Hooper, A. T., Böhlen, P., & Hicklin, D. J. (2002) · The Journal of Experimental Medicine · doi:10.1084/jem.20020072 · Cited by 153
VEGFR2 is selectively expressed by FOXP3high CD4+ Treg
Suzuki, H. Y., Onishi, H., 和田, 純., Yamasaki, A., Tanaka, H., Nakano, K., Morisaki, T., & Katano, M. (2009) · European Journal of Immunology · doi:10.1002/eji.200939887 · Cited by 136
Targeting autocrine and paracrine VEGF receptor pathways inhibits human lymphoma xenografts in vivo
Wang, E. S., Teruya‐Feldstein, J., Wu, Y. L., Zhu, Z., Hicklin, D. J., & Moore, M. A. S. (2004) · Blood · doi:10.1182/blood-2004-01-0226 · Cited by 128
Niederman, T. M. J., Ghogawala, Z., Carter, B. S., Tompkins, H. S., Russell, M. M., & Mulligan, R. C. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.092562399 · Cited by 125
Feng, D., Nagy, J. A., Brekken, R. A., Pettersson, A. F., Manseau, E. J., Pyne, K., Mulligan, R. C., Thorpe, P. E., Dvorak, H. F., & Dvořàk, A. M. (2000) · Journal of Histochemistry & Cytochemistry · doi:10.1177/002215540004800412 · Cited by 121
Angiogenesis: a curse or cure?
Gupta, K., & Zhang, J. (2005) · Postgraduate Medical Journal · doi:10.1136/pgmj.2004.023309 · Cited by 114
Bukczynski, J., Wen, T., Ellefsen, K., Gauldie, J., & Watts, T. H. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0306567101 · Cited by 109
UpGene: Application of a Web‐Based DNA Codon Optimization Algorithm
Gao, W., Rzewski, A., Sun, H., Robbins, P. D., & Gambotto, A. A. (2004) · Biotechnology Progress · doi:10.1021/bp0300467 · Cited by 109
Vascular endothelial growth factor chimeric toxin is highly active against endothelial cells.
Arora, N., Masood, R., Zheng, T. Z., Cai, J., Smith, D. L., & Gill, P. S. (1999) · PubMed · Cited by 107
Zhu, Z., Rockwell, P., Lu, D., Kotanides, H., Pytowski, B., Hicklin, D. J., Böhlen, P., & Witte, L. (1998) · PubMed · Cited by 106
Wada, S., Tsunoda, T., Baba, T., Primus, F. J., Kuwano, H., Shibuya, M., & Tahara, H. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-3759 · Cited by 102
Lamers, C. H. J., Langeveld, S. C. L., Ruijven, C. M. G.-V., Debets, R., Sleijfer, S., & Gratama, J. W. (2007) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-007-0330-3 · Cited by 94
Maeurer, M. J., Gollin, S. M., Storkus, W. J., Swaney, W. P., Karbach, J., Martin, D., Castelli, C., Salter, R. D., Knuth, A., & Lotze, M. T. (1996) · PubMed · Cited by 91
Friedmann‐Morvinski, D., Bendavid, A., Waks, T., Schindler, D., & Eshhar, Z. (2004) · Blood · doi:10.1182/blood-2004-09-3737 · Cited by 84
Seavey, M. M., Maciag, P., Al-Rawi, N., Sewell, D. A., & Paterson, Y. Y. W. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0803742 · Cited by 80
Ran, S., Huang, X., Downes, A., et al. (2003) · Neoplasia · doi:10.1016/s1476-5586(03)80023-4 · Cited by 44
Immunity against Tumor Angiogenesis Induced by a Fusion Vaccine with Murine β-Defensin 2 and mFlk-1
Wang, Y., Wang, G., Wen, Y., Wang, L. Y., Chen, X., Chen, P., Kan, B., Li, J., Huang, C., Lü, Y., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1587 · Cited by 30
Rakhmilevich, A. L., Hooper, A. T., Hicklin, D. J., & Sondel, P. M. (2004) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.969.3.8 · Cited by 27
Combined Antiangiogenic and Immune Therapy of Prostate Cancer
Huang, X., Raskovalova, T., Lokshin, A. E., Krasinskas, A. M., Devlin, J. E., Watkins, S. C., Wolf, S. F., & Gorelik, E. (2005) · Angiogenesis · doi:10.1007/s10456-005-2893-y · Cited by 17
Targeting Tumor Vasculature Using VEGF-Toxin Conjugates
Ramakrishnan, S., Wild, R., & Nojima, D. (2003) · Humana Press eBooks · doi:10.1385/1-59259-114-0:219 · Cited by 10
Cited by
Adoptive immunotherapy for cancer: harnessing the T cell response
Restifo, N. P., Dudley, M. E., & Rosenberg, S. A. (2012) · Nature Reviews Immunology · doi:10.1038/nri3191 · Cited by 1,688
Self-citationPrecision Tumor Recognition by T Cells With Combinatorial Antigen-Sensing Circuits
Roybal, K. T., Rupp, L. J., Morsut, L., Walker, W. J., McNally, K. A., Park, J. S., & Lim, W. A. (2016) · Cell · doi:10.1016/j.cell.2016.01.011 · Cited by 1,000
Maalej, K. M., Merhi, M., Inchakalody, V. P., Mestiri, S., Alam, M., Maccalli, C., Cherif, H., Uddin, S., Steinhoff, M., Marincola, F. M., et al. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01723-z · Cited by 618
Jackson, H. J., Rafiq, S., & Brentjens, R. J. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.36 · Cited by 613
Design and development of therapies using chimeric antigen receptor‐expressing T cells
Dotti, G., Gottschalk, S., Savoldo, B., & Brenner, M. K. (2014) · Immunological Reviews · doi:10.1111/imr.12131 · Cited by 508
Metadata
- Authors
- Chinnasamy, D., Yu, Z., Theoret, M. R., Zhao, Y., Shrimali, R. K., Morgan, R. A., Feldman, S. A., Restifo, N. P., & Rosenberg, S. A.
- Venue
- Journal of Clinical Investigation
- Published
- 2010-11-01
- Volume
- 120
- Issue
- 11
- Pages
- 3953-3968
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W2008324933
- Cited by
- 253
- References
- 84
- FWCI
- 6.27
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.